Neuroscience News & Analysis
2 articles
Market Mood
AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
AbbVie (ABBV) management projects $12.7 billion in sales from its neuroscience division this year. The company is focusing on expanding its portfolio in this area, which is becoming an increasingly significant part of its operations. This projection reflects AbbVie's strategy to leverage its existing resources and expertise to capitalize on growth in the neuroscience market. For investors, the anticipated earnings could signal positive momentum for AbbVie's stock performance as it strengthens its market position.
Read More: AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa
Eli Lilly and Company (LLY) received FDA approval for its weight loss pill, Foundayo, which can be taken without food or water restrictions, starting at $25 per month. The company also announced its acquisition of Centessa Pharmaceuticals for $7.8 billion, focusing on neurological treatments. These developments may enhance LLY's market position, particularly in the weight loss and neuroscience sectors. Investor sentiment is influenced by the dual impact of the weight loss pill and the strategic acquisition aimed at addressing complex medical conditions.
Read More: Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa